Publications
Structural basis for complement receptor engagement and virus neutralization through Epstein-Barr virus gp350. Immunity. 58, 295-308.e5
(2025) Structural basis for complement receptor engagement and virus neutralization through Epstein-Barr virus gp350. Immunity. 58, 295-308.e5
(2025) Structure-guided discovery of viral proteins that inhibit host immunity. Cell. 10.1016/j.cell.2024.12.035
(2025) Structures of TGF-β with betaglycan and signaling receptors reveal mechanisms of complex assembly and signaling.. Nat Commun. 16, 1778
(2025) A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins. J Med Chem. 68, 1092-1112
(2025) A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins. J Med Chem. 68, 1092-1112
(2025) A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins. J Med Chem. 68, 1092-1112
(2025) A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins. J Med Chem. 68, 1092-1112
(2025) A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins. J Med Chem. 68, 1092-1112
(2025) A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins. J Med Chem. 68, 1092-1112
(2025) Targeting transcription factors through an IMiD independent zinc finger domain. EMBO Mol Med. 17, 1393-1416
(2025) Targeting transcription factors through an IMiD independent zinc finger domain. EMBO Mol Med. 17, 1393-1416
(2025) (2025) Topobexin targets the Topoisomerase II ATPase domain for beta isoform-selective inhibition and anthracycline cardioprotection. Nat Commun. 16, 4928
(2025) Topobexin targets the Topoisomerase II ATPase domain for beta isoform-selective inhibition and anthracycline cardioprotection. Nat Commun. 16, 4928
(2025) Topobexin targets the Topoisomerase II ATPase domain for beta isoform-selective inhibition and anthracycline cardioprotection. Nat Commun. 16, 4928
(2025) (2025) (2025)